



**California State Board of Pharmacy**

1625 N. Market Blvd, Suite N219, Sacramento, CA 95834  
Phone (916) 574-7900  
Fax (916) 574-8618  
www.pharmacy.ca.gov

BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY  
DEPARTMENT OF CONSUMER AFFAIRS  
GOVERNOR EDMUND G. BROWN JR.

**NOTICE OF MEETING AND AGENDA**  
**Communication and Public Education Committee**  
**September 8, 2016**

---

**DATE:** September 8, 2016, at 9:30 a.m.

**PLACE:** Department of Consumer Affairs  
First Floor Hearing Room  
1625 North Market Blvd.  
Sacramento, CA 95834

*NOTE: Pharmacists and pharmacy technicians who attend in person may be awarded 2 hours of CE, in accordance with the Board's CE policy. Sign in and sign out on the day of the meeting will be required for the CE credit.*

For verification of the meeting, call (916) 574-7918 or (916) 574-7900 or access the Board's Web site at [www.pharmacy.ca.gov](http://www.pharmacy.ca.gov). Meeting materials should be available on the board's Web site at [www.pharmacy.ca.gov](http://www.pharmacy.ca.gov) by September 2, 2016.

---

*The meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Laura Hendricks at (916) 574-7918, by emailing [laura.hendricks@dca.ca.gov](mailto:laura.hendricks@dca.ca.gov) or sending a written request to the Board of Pharmacy, 1625 N. Market Blvd., Suite N-219, Sacramento, CA 95834. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.*

*Discussion and action may be taken on any item on the agenda. The time and order of agenda items are subject to change at the discretion of the Committee Chairperson and may be taken out of order. In accordance with the Bagley-Keene Open Meeting Act, all meetings of the Board are open to the public.*

*NOTE: \*Government Code Section 11125.7 provides the opportunity for the public to address each agenda item during discussion or consideration by the committee or prior to the committee taking any action on said item. Members of the public will be provided appropriate opportunities to comment on any issues before the committee, but the Committee Chairperson may, at his or her discretion, apportion available time among those who wish to speak. Individuals may appear before the committee to discuss items not on the agenda; however, the committee can neither discuss nor take official action on these items at the time of the same meeting (Government Code Sections 11125, 11125.7(a)).*

## Agenda

### Call to Order

9:30 a.m.

1. Call to Order and Establishment of Quorum
2. Public Comment for Items Not on the Agenda, Matters for Future Meetings\*  
*\*(Note: the committee may not discuss or take action on any matter raised during the public comment section that is not included on this agenda, except to decide to place the matter on the agenda of a future meeting. Government Code Sections 11125 & 11125.7(a))*
3. Update and Discussion on the Development of a Revised Patient Consultation Survey Questionnaire
  - a. Review and Discussion of Similarly Conducted Surveys on Patient Consultations
  - b. Review and Discussion of the Department of Consumer Affairs Developed Patient Consultation Survey
4. Update and Discussion on the Final Rule Implementing Section 1557 of the Affordable Care Act (ACA) Regarding Nondiscrimination in Health Programs and Activities, Specifically Including its Impact on Pharmacy Translations and Interpretations
  - a. Overview and Summary
  - b. Board Statutes and Regulations Impacted
  - c. Development of Prescription Label Translations of Directions for Use Pursuant to Business and Professions Code section 4076.6
5. Update and Discussion on Development of FAQs Received From [ask.inspector@dca.ca.gov](mailto:ask.inspector@dca.ca.gov)
6. Discussion and Consideration of Naloxone-Related Matters
  - a. Communication to the California Healing Art Boards Regarding Naloxone
  - b. Naloxone FAQs
  - c. SB 833 (Committee on Budget and Fiscal Review, Health, Chapter 30, Statutes of 2016)
  - d. Discussion on Federal Legislation: US S. 524 – Comprehensive Addiction and Recovery Act of 2016
    - i. Lali's Law
    - ii. Provisions regarding Partial Fills for Schedule II
7. Discussion on the Development of FAQs for SB 493 Related Items
8. Discussion on CE Courses Available for Naloxone, Self-Administered Hormonal Contraception and Nicotine Replacement Therapy under Protocols
9. Update and Discussion on Resources Available on the Board's Website
10. Discussion of a Board-Developed Bulletin Board Message and Related Communication Materials

11. Update and Discussion on SB 1193 (Hill) Requiring Pharmacists, Intern Pharmacists, Pharmacy Technician and Designated Representatives Licensed in California Join the Board's E-mail Notification List
12. Communication Plan for Consumers and Licensees
13. Update and Discussion on the Forty-Fifth Annual Report of the Research Advisory Panel of California for 2015 Regarding Controlled Drugs Research
14. Board Publications – Review and Recommendations for changes
  - a. Counterfeit Prescription Drugs: Protect Yourself, Your Family and Your Pets
  - b. Buying Prescription Medications Online: Are the Drugs You Buy Real or Fake?
15. Update on *The Script* Newsletter
16. Update on Media Activity
17. Update on Public Outreach Activities Conducted by the Board
18. Review and Discussion of News or Journal Articles
19. Review and Discussion of the California Department of Public Health's Comparison Between the Centers for Disease Control and Prevention's *Guidelines for Prescribing Opioids for Chronic Pain* and the Medical Board of California's *Guidelines for Prescribing Controlled Substances for Pain*
20. Future Meeting Dates
  - a. December 1, 2016

**Adjournment**

**2:00 p.m.**